Introduction: Psoriasis is a chronic inflammatory skin disease characterized by dysregulation
of the immune system and release of pro-inflammatory mediators. Drugs available for …

Introduction: Psoriasis is a common skin disorder characterized by chronic inflammatory
lesions that are frequently vexing for patients and difficult for physicians to treat. Although …

Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a
prolonged and safe control of the disease is needed. Current anti-psoriatic treatments show …

Objectives The aim of this paper is to present our personal as well as literature-sourced real-
world evidenced on apremilast use in psoriasis patients with serious baseline comorbidities …

Apremilast (Otezla®) is an oral phosphodiesterase 4 inhibitor indicated for the twice-daily
treatment of adults with psoriasis and psoriatic arthritis (PsA). Its use in these patient …

Background Experience in the use of apremilast in clinical practice complements the
information available from pivotal clinical trials. Materials and methods Following a review of …

ABSTRACT Introduction: Psoriasis (PSo) is a chronic inflammatory skin disease associated
with co-morbidities such as hypertension, diabetes, dyslipidemia and metabolic syndrome. It …

Objective: To review the pharmacology, efficacy, and safety of apremilast and determine its
role relative to other agents in the treatment of psoriasis and psoriatic arthritis. Data Sources …

Background• An electronic literature search was performed by one reviewer using the
PubMed database on April 7, 2020 with the following search terms (apremilast AND …

Apremilast (Otezla®) is an orally administered, small molecule inhibitor of
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …